Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
На конгрессе ESMO представили результаты российского исследования препарата трифлуридин/типирацил у пациентов с рефрактерным метастатическим колоректальным раком
На конгрессе ESMO представили результаты российского исследования препарата трифлуридин/типирацил у пациентов с рефрактерным метастатическим колоректальным раком
Материалы доступны только для специалистов сферы здравоохранения.
Чтобы посмотреть материал полностью
Авторизуйтесь
или зарегистрируйтесь.
Полный текст
Список литературы
1. World Health Organisation. Globocan (2012), colorectal cancer. http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx?cancer=colorectal
2. Cancer Research UK. Worldwide cancer statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/mortality#hea...
3. American Cancer Society. Survival Rates for Colorectal Cancer, by Stage. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
4. European Medicines Agency. EPAR Lonsurf. http://www.ema. europa. eu/ema/
5. NICE TA405. www.nice.org.uk/guidance/TA405
6. National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
7. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.
8. Van Cutsem E et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–422.
2. Cancer Research UK. Worldwide cancer statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/mortality#hea...
3. American Cancer Society. Survival Rates for Colorectal Cancer, by Stage. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
4. European Medicines Agency. EPAR Lonsurf. http://www.ema. europa. eu/ema/
5. NICE TA405. www.nice.org.uk/guidance/TA405
6. National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
7. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.
8. Van Cutsem E et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–422.
2. Cancer Research UK. Worldwide cancer statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/mortality#hea...
3. American Cancer Society. Survival Rates for Colorectal Cancer, by Stage. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
4. European Medicines Agency. EPAR Lonsurf. http://www.ema. europa. eu/ema/
5. NICE TA405. www.nice.org.uk/guidance/TA405
6. National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
7. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.
8. Van Cutsem E et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–422.
________________________________________________
2. Cancer Research UK. Worldwide cancer statistics. http://www.cancerresearchuk.org/health-professional/cancer-statistics/worldwide-cancer/mortality#hea...
3. American Cancer Society. Survival Rates for Colorectal Cancer, by Stage. https://www.cancer.org/cancer/colon-rectal-cancer/detection-diagnosis-staging/survival-rates.html
4. European Medicines Agency. EPAR Lonsurf. http://www.ema. europa. eu/ema/
5. NICE TA405. www.nice.org.uk/guidance/TA405
6. National Comprehensive Cancer Network (NCCN). NCCN Guidelines Insights: Colon Cancer, Version 2.2018.
7. National Comprehensive Cancer Network (NCCN). NCCN Guidelines for Patients: Rectal Cancer, Version 1.2017.
8. Van Cutsem E et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386–422.
Авторы
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.